Johanna A van der Zande
Overview
Explore the profile of Johanna A van der Zande including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
3
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Zande J, Johnson M, Roos-Hesselink J
Eur Heart J
. 2024 Nov;
46(6):579-581.
PMID: 39607795
No abstract available.
2.
van der Zande J, Ramlakhan K, Prokselj K, Munoz-Ortiz E, Baroutidou A, Lipczynska M, et al.
Am J Cardiol
. 2024 Aug;
230:27-36.
PMID: 39122205
Angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are not recommended during the second and third trimester because of the significant risk of congenital anomalies associated with their use....
3.
van der Zande J, Greutmann M, Tobler D, Ramlakhan K, Cornette J, Ladouceur M, et al.
Eur J Heart Fail
. 2024 Jun;
26(7):1561-1570.
PMID: 38837327
Aims: Data on diuretic use in pregnancy are limited and inconsistent, and consequently it remains unclear whether they can be used safely. Our study aims to evaluate the perinatal outcomes...
4.
van Maldegem L, van der Zande J, van Werkhoven L, Ewing-Graham P, Heemskerk-Gerritsen B, van Doorn H
Acta Obstet Gynecol Scand
. 2024 May;
103(7):1283-1291.
PMID: 38695570
Introduction: Recurrent postmenopausal bleeding (PMB) occurs in 6%-25% of postmenopausal women who have experienced a previous episode of PMB. The question of whether recurrent PMB leads to a higher risk...
5.
Kempers E, van der Zande J, Janssen P, Cornette J, Roos-Hesselink J, Kruip M
Res Pract Thromb Haemost
. 2024 Jan;
8(1):102295.
PMID: 38268520
Background: The effects of antiplatelet therapy on menstrual bleeding have not been well characterized. Objectives: To systematically review the effects of antiplatelet therapy on menstrual bleeding. Methods: A literature search...
6.
van der Zande J, Tutarel O, Ramlakhan K, van der Bosch A, Bordese R, Zengin E, et al.
Open Heart
. 2023 Aug;
10(2).
PMID: 37550057
Objective: Ebstein's anomaly is a rare congenital cardiac condition and data regarding pregnancy outcomes in this patient group are scarce. We evaluated the maternal and perinatal risks of pregnancy in...
7.
Wander G, van der Zande J, Patel R, Johnson M, Roos-Hesselink J
Expert Rev Cardiovasc Ther
. 2023 Jul;
21(8):587-599.
PMID: 37470417
Introduction: Congenital heart disease (CHD) is the most common cardiac disorder in pregnancy in the western world (around 80%). Due to improvements in surgical interventions more women with CHD are...
8.
van der Zande J, Cornette J, Roos-Hesselink J, Flint R
Int Breastfeed J
. 2023 Apr;
18(1):21.
PMID: 37060099
Background: Mothers requiring the antiarrhythmic agent flecainide are often advised not to breastfeed, because of the lack of data concercing neonatal effects and flecainide plasma concentrations following maternal exposure as...
9.
Roos-Hesselink J, van der Zande J, Johnson M
Eur Heart J
. 2023 Feb;
44(17):1541-1543.
PMID: 36748201
No abstract available.
10.
Ramlakhan K, van der Zande J, Roos-Hesselink J, Franx A, Cornette J
BJOG
. 2023 Jan;
130(7):813-822.
PMID: 36655488
Objective: To assess the long-term quality of life (QoL) after obstetric Intensive Care Unit (ICU) admission. Design: Cross-sectional survey study. Setting: Tertiary care centre. Population: Women admitted to the level...